1ST Biotherapeutics, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.1stbio.com
A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
Phase 1
Recruiting
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)Parkinson Disease Psychosis
- Interventions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- 1ST Biotherapeutics, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT05995782
- Locations
- 🇰🇷
Seoul National University, Seoul, Korea, Republic of
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: Phase Ib dose-expansion of FB849 monotherapyDrug: Phase Ia dose-escalation part of FB849 Monotherapy
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- 1ST Biotherapeutics, Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT05761223
- Locations
- 🇺🇸
Summit Cancer Centers - Spokane Valley, Spokane, Washington, United States
🇺🇸Mary Crowley Cancer Research Center, Dallas, Texas, United States
🇺🇸NEXT Oncology San Antonio, San Antonio, Texas, United States
Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- 1ST Biotherapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04165837
- Locations
- 🇺🇸
PAREXEL, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath